ISSN: 2225-8329
Open access
Chronic diseases are defined broadly as conditions that last 1 year or more and require ongoing medical attention or limit activities of daily living or both. The treatment for this disease is a costly procedure that requires specific resources. This is especially true for Malaysia, where many patients with chronic disease belong to the elderly group, who do not have any source of income and therefore cannot afford the treatment costs, hence, increase the risk of financial distress. It is important to note that, monetary costs are not the only driver of financial distress. Other factors such as patients’ experiences and feelings about financial conditions arising from the treatment can negatively affect patient’s outcomes, quality of life, financial well-being, psycho-social health, and ultimately the patient’s ability to deal with the challenges associated with the treatment. The above-mentioned economic and social changes caused by the treatments of disease and disease itself to patients are known as Financial Toxicity. Knowing the data on financial toxicity will enable us to integrate the financial discussions into treatment plans that will allow for selection of cheaper but equally effective interventions and gives patients time to seek resources that can help them better finance care and avoid catastrophic health spending. However, despite the importance of this topic, little is known about the financial toxicity especially on those with chronic kidney disease. Using primary data (interview and questionnaires), this proposed research expected to come out with a model to assess the degree of financial toxicity for chronic kidney disease patients in Malaysia.
Agarwal, S. K., Dash, S. C., Irshad, M., Raju, S., Singh, R., & Pandey, R. M. (2015). Prevalence of chronic renal failure in adults in Delhi, India. Nephrology Dialysis Transplantation, 20(8), 1638-1642.
Ahlawat, R., Tiwari, P., & D’Cruz, S. (2017). Direct Cost for Treating Chronic Kidney Disease at an Outpatient Setting of a Tertiary Hospital: Evidence from a Cross-Sectional Study. Value in health regional issues, 12, 36-40.
Bestvina, C. M., Zullig, L. L., & Zafar, Y. S. (2014). The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature. Future Oncology, 10(14), 2189-2199.
Casilla-Lennon, M. M., Choi, S. K., Deal, A. M., Bensen, J. T., Narang, G., Filippou, P., ... & Smith, A. (2018). Financial toxicity among patients with bladder cancer: reasons for delay in care and effect on quality of life. The Journal of urology, 199(5), 1166-1173.
Delgado-Guay, M., Ferrer, J., Rieber, A. G., Rhondali, W., Tayjasanant, S., Ochoa, J., ... & Bruera, E. (2015). Financial distress and its associations with physical and emotional symptoms and quality of life among advanced cancer patients. The oncologist, 20(9), 10
92-1098.
De Souza, J. A., & Wong, Y. N. (2013). Financial distress in cancer patients. Journal of Medicine and the Person, 11(2), 73-77.
De Souza, J. A., Yap, B., Hlubocky, F. J., Ratain, M. J., Cella, D., & Daugherty, C. (2013). The development of a financial toxicity patient-reported outcome instrument (PRO) in cancer.
Durber, K., Halkett, G. K., McMullen, M., & Nowak, A. K. (2021). Measuring financial toxicity in Australian cancer patients–Validation of the COmprehensive Score for financial Toxicity (FACT COST) measuring financial toxicity in Australian cancer patients. Asia?Pacific Journal of Clinical Oncology.
Edward, J. S., Rayens, M. K., Zheng, X., & Vanderpool, R. C. (2021). The association of health insurance literacy and numeracy with financial toxicity and hardships among colorectal cancer survivors. Supportive Care in Cancer, 1-8.
Ehlers, M., Bjurlin, M., Gore, J., Pruthi, R., Narang, G., Tan, R., ... & Smith, A. (2021). A national cross-sectional survey offinancial toxicity among bladder cancer patients. In Urologic Oncology: Seminars and Original Investigations (Vol. 39, No. 1, pp. 76-e
Esselen, K. M., Stack-Dunnbier, H., Gompers, A., & Hacker, M. R. (2021). Crowdsourcing to measure financial toxicity in gynecologic oncology. Gynecologic Oncology.
Gordon, L. G., Merollini, K., Lowe, A., & Chan, R. J. (2017). Financial toxicity-what it is and how to measure it. In Cancer Forum (Vol. 41, No. 2, p. 30). The Cancer Council Australia.
Gordon, L. G., Walker, S. M., Mervin, M. C., Lowe, A., Smith, D. P., Gardiner, R. A., & Chambers, S. K. (2017). Financial toxicity: apotential side effect of prostate cancer treatment among Australian men. European journal of cancer care, 26(1), e12392.
Laba, T. L., Essue, B. M., & Jan, S. (2015). Financing options to sustain Medicare: are we committed to universalism. Med J Aust, 203(6), 244-5.
Mejri, N., Berrazega, Y., Boujnah, R., Rachdi, H., El Benna, H., Labidi, S., & Boussen, H. (2021). Assessing the financial toxicity in Tunisian cancer patients using the Comprehensive Score for Financial Toxicity (COST). Supportive Care in Cancer, 1-7.
Nugent, R. A., Fathima, S. F., Feigl, A. B., & Chyung, D. (2011). The burden of chronic kidney disease on developing nations: a 21st century challenge in global health. Nephron Clinical Practice, 118(3), c269-c277.
Politi, M. C., Yen, R. W., Elwyn, G., O'Malley, A. J., Saunders, C. H., Schubbe, D., ... & Durand, M. A. (2021). Women Who Are Young, Non?White, and with Lower Socioeconomic Status Report Higher Financial Toxicity up to 1 Year After Breast Cancer Surgery: A Mixed?Effects Regression Analysis. The oncologist, 26(1), e142-e152.
Smith, K. (2015). Financial toxicity impacts treatment adherence: oncologists must address costs with their patients. Am Health Drug Benefits, 8(3), 10-1.
Ting, C. Y., Teh, G. C., Yu, K. L., Alias, H., Tan, H. M., & Wong, L. P. (2020). Financial toxicity and its associations with health-related quality of life among urologic cancer patients in an upper middle-income country. Supportive Care in Cancer, 28(4), 1703-1715.
Ver Hoeve, E. S., Ali-Akbarian, L., Price, S. N., Lothfi, N. M., & Hamann, H. A. (2021). Patient-reported financial toxicity, quality of life, and health behaviors in insured US cancer survivors. Supportive Care in Cancer, 29(1), 349-358.
Williams, C. P., Gallagher, K. D., Deehr, K., Aswani, M. S., Azuero, A., Daniel, C. L., ... & Rocque, G. B. (2021). Quantifying treatment preferences and their association with financial toxicity in women with breast cancer. Cancer, 127(3), 449-457.
Workman, P., Draetta, G. F., Schellens, J. H., & Bernards, R. (2017). How much longer will we put up with $100,000 cancer drugs?. Cell, 168(4), 579-583.
Zafar, Y. S. (2015). Financial toxicity of cancer care: It’s time to intervene. Journal of the National Cancer Institute, 108(5)
In-Text Citation: (Bulot, 2022)
To Cite this Article: Bulot, N. (2022). Conceptual Paper: Developing Financial Toxicity Measurement Model for Patients with Chronic Kidney Disease in Malaysia. International Journal of Academic Research in Accounting Finance and Management Sciences, 12(3), 573–580.
Copyright: © 2022 The Author(s)
Published by Human Resource Management Academic Research Society (www.hrmars.com)
This article is published under the Creative Commons Attribution (CC BY 4.0) license. Anyone may reproduce, distribute, translate and create derivative works of this article (for both commercial and non-commercial purposes), subject to full attribution to the original publication and authors. The full terms of this license may be seen at: http://creativecommons.org/licences/by/4.0/legalcode